Literature DB >> 15890937

Strain-specific T-cell suppression and protective immunity in patients with chronic hepatitis C virus infection.

Kazushi Sugimoto1, David E Kaplan, Fusao Ikeda, Jin Ding, Jonathan Schwartz, Frederick A Nunes, Harvey J Alter, Kyong-Mi Chang.   

Abstract

Hepatitis C virus (HCV) frequently persists with an apparently ineffective antiviral T-cell response. We hypothesized that some patients may be exposed to multiple HCV subtypes and that strain-specific T cells could contribute to the viral dynamics in this setting. To test this hypothesis, CD4 T-cell responses to three genotype 1a-derived HCV antigens and HCV antibody serotype were examined in chronically HCV infected (genotypes 1a, 1b, 2, 3, and 4) and spontaneously HCV recovered subjects. Consistent with multiple HCV exposure, 63% of patients infected with genotypes 2 to 4 (genotypes 2-4) and 36% of those infected with genotype 1b displayed CD4 T-cell responses to 1a-derived HCV antigens, while 29% of genotype 2-4-infected patients showed serotype responses to genotype 1. Detection of 1a-specific T cells in patients without active 1a infection suggested prior self-limited 1a infection with T-cell-mediated protection from 1a but not from non-1a viruses. Remarkably, CD4 T-cell responses to 1a-derived HCV antigens were weakest in patients with homologous 1a infection and greater in non-1a-infected patients: proportions of patients responding were 19% (1a), 36% (1b), and 63% (2-4) (P = 0.0006). Increased 1a-specific CD4 T-cell responsiveness in non-1a-infected patients was not due to increased immunogenicity or cross-reactivity of non-1a viruses but directly related to sequence divergence. We conclude that the T-cell response to the circulating virus is either suppressed or not induced in a strain-specific manner in chronically HCV infected patients and that, despite their ability to clear one HCV strain, patients may be reinfected with a heterologous strain that can then persist. These findings provide new insights into host-virus interactions in HCV infection that have implications for vaccine development.

Entities:  

Mesh:

Year:  2005        PMID: 15890937      PMCID: PMC1112102          DOI: 10.1128/JVI.79.11.6976-6983.2005

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  47 in total

1.  Overcoming original (antigenic) sin.

Authors:  D E Anderson; M P Carlos; L Nguyen; J V Torres
Journal:  Clin Immunol       Date:  2001-11       Impact factor: 3.969

2.  Viral clearance in hepatitis C (1b) infection: relationship with human leukocyte antigen class II in a homogeneous population.

Authors:  L J Fanning; J Levis; E Kenny-Walsh; F Wynne; M Whelton; F Shanahan
Journal:  Hepatology       Date:  2000-06       Impact factor: 17.425

3.  Hepatitis C virus-specific T-cell reactivity during interferon and ribavirin treatment in chronic hepatitis C.

Authors:  M E Cramp; S Rossol; S Chokshi; P Carucci; R Williams; N V Naoumov
Journal:  Gastroenterology       Date:  2000-02       Impact factor: 22.682

4.  Cellular immune responses persist and humoral responses decrease two decades after recovery from a single-source outbreak of hepatitis C.

Authors:  A Takaki; M Wiese; G Maertens; E Depla; U Seifert; A Liebetrau; J L Miller; M P Manns; B Rehermann
Journal:  Nat Med       Date:  2000-05       Impact factor: 53.440

5.  Hepatitis C virus-specific CD4+ T cell response after liver transplantation occurs early, is multispecific, compartmentalizes to the liver, and does not correlate with recurrent disease.

Authors:  C A Schirren; M C Jung; T Worzfeld; M Mamin; G Baretton; J T Gerlach; N H Gruener; R Zachoval; M Houghton; H G Rau; G R Pape
Journal:  J Infect Dis       Date:  2001-03-14       Impact factor: 5.226

6.  Two successive hepatitis C virus infections in an intravenous drug user.

Authors:  B Proust; F Dubois; Y Bacq; S Le Pogam; S Rogez; R Levillain; A Goudeau
Journal:  J Clin Microbiol       Date:  2000-08       Impact factor: 5.948

7.  Concordance between hepatitis C virus serotyping assays.

Authors:  R G Gish; K P Qian; S Quan; Y L Xu; I Pike; A Polito; R DiNello; J Y Lau
Journal:  J Viral Hepat       Date:  1997       Impact factor: 3.728

8.  CD4 T helper type 1 and regulatory T cells induced against the same epitopes on the core protein in hepatitis C virus-infected persons.

Authors:  Angus J MacDonald; Margaret Duffy; Miriam T Brady; Susan McKiernan; William Hall; John Hegarty; Michael Curry; Kingston H G Mills
Journal:  J Infect Dis       Date:  2002-02-28       Impact factor: 5.226

9.  Differential CD4(+) and CD8(+) T-cell responsiveness in hepatitis C virus infection.

Authors:  K M Chang; R Thimme; J J Melpolder; D Oldach; J Pemberton; J Moorhead-Loudis; J G McHutchison; H J Alter; F V Chisari
Journal:  Hepatology       Date:  2001-01       Impact factor: 17.425

10.  The outcome of hepatitis C virus infection is predicted by escape mutations in epitopes targeted by cytotoxic T lymphocytes.

Authors:  A L Erickson; Y Kimura; S Igarashi; J Eichelberger; M Houghton; J Sidney; D McKinney; A Sette; A L Hughes; C M Walker
Journal:  Immunity       Date:  2001-12       Impact factor: 31.745

View more
  16 in total

Review 1.  Adaptive immunity to the hepatitis C virus.

Authors:  Christopher M Walker
Journal:  Adv Virus Res       Date:  2010       Impact factor: 9.937

2.  Modulation of Hepatitis C Virus-Specific CD8 Effector T-Cell Function with Antiviral Effect in Infectious Hepatitis C Virus Coculture Model.

Authors:  Keisuke Ojiro; Xiaowang Qu; Hyosun Cho; Jang-June Park; Annelise Vuidepot; Nikolai Lissin; Peter E Molloy; Alan Bennett; Bent K Jakobsen; David E Kaplan; James L Riley; Kyong-Mi Chang
Journal:  J Virol       Date:  2017-04-28       Impact factor: 5.103

Review 3.  Insights From Antiviral Therapy Into Immune Responses to Hepatitis B and C Virus Infection.

Authors:  Barbara Rehermann; Robert Thimme
Journal:  Gastroenterology       Date:  2018-09-26       Impact factor: 22.682

4.  Physiological functions and clinical implications of fibrinogen-like 2: A review.

Authors:  Genyan Yang; W Craig Hooper
Journal:  World J Clin Infect Dis       Date:  2013-08-25

5.  Immunologic evidence for lack of heterologous protection following resolution of HCV in patients with non-genotype 1 infection.

Authors:  Julian Schulze Zur Wiesch; Georg M Lauer; Joerg Timm; Thomas Kuntzen; Martin Neukamm; Andrew Berical; Andrea M Jones; Brian E Nolan; Steve A Longworth; Victoria Kasprowicz; Cory McMahon; Alysse Wurcel; Ansgar W Lohse; Lia L Lewis-Ximenez; Raymond T Chung; Arthur Y Kim; Todd M Allen; Bruce D Walker
Journal:  Blood       Date:  2007-05-02       Impact factor: 22.113

6.  Human leukocyte antigen class II associations with hepatitis C virus clearance and virus-specific CD4 T cell response among Caucasians and African Americans.

Authors:  Rebecca A Harris; Kazushi Sugimoto; David E Kaplan; Fusao Ikeda; Malek Kamoun; Kyong-Mi Chang
Journal:  Hepatology       Date:  2008-07       Impact factor: 17.425

7.  Identification and in vitro expansion of functional antigen-specific CD25+ FoxP3+ regulatory T cells in hepatitis C virus infection.

Authors:  Hirotoshi Ebinuma; Nobuhiro Nakamoto; Yun Li; David A Price; Emma Gostick; Bruce L Levine; J Tobias; William W Kwok; Kyong-Mi Chang
Journal:  J Virol       Date:  2008-03-12       Impact factor: 5.103

8.  Functional restoration of HCV-specific CD8 T cells by PD-1 blockade is defined by PD-1 expression and compartmentalization.

Authors:  Nobuhiro Nakamoto; David E Kaplan; Jennifer Coleclough; Yun Li; Mary E Valiga; Mary Kaminski; Abraham Shaked; Kim Olthoff; Emma Gostick; David A Price; Gordon J Freeman; E John Wherry; Kyong-Mi Chang
Journal:  Gastroenterology       Date:  2008-02-17       Impact factor: 22.682

9.  Foxp3 and Treg cells in HIV-1 infection and immuno-pathogenesis.

Authors:  Derek Holmes; Qi Jiang; Liguo Zhang; Lishan Su
Journal:  Immunol Res       Date:  2008       Impact factor: 2.829

Review 10.  Coinfection with HIV-1 and HCV--a one-two punch.

Authors:  Arthur Y Kim; Raymond T Chung
Journal:  Gastroenterology       Date:  2009-06-21       Impact factor: 22.682

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.